Thomas J. DesRosier

Thomas J. DesRosier

Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal OfficeratSeres Therapeutics· In proxies 2024–2025

Pay in FY2025-9% from the year before · Seres Therapeutics stock -10.5% the same year

Thomas J. DesRosier was paid $1.1M in FY2025 (Dec), down 9%. Seres Therapeutics stock fell 10.5% that year.

Pay$100 in the stock at the end of FY23 → $53
Pay is from the Summary Compensation Table of each Seres Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Seres TherapeuticsPublic company · 2 yr
    • Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer2024 – Present · 2 yrStock in role -93%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?